Abstract:In Oncology, trials evaluating drug combinations are becoming more common. While combination therapies bring the potential for greater efficacy, they also create unique challenges for ensuring drug safety. In Phase-I dose escalation trials of drug combinations, model-based approaches enable efficient use of information gathered, but the models need to account for trial complexities: appropriate modeling of interactions becomes increasingly important with growing numbers of drugs being tested simultaneously in a given trial. In principle, we can use data from multiple arms testing varying combinations to jointly estimate toxicity of the drug combinations. However, such efforts have highlighted limitations when modelling drug-drug interactions in the Bayesian Logistic Regression Model (BLRM) framework used to ensure patient safety. Previous models either do not account for non-monotonicity due to antagonistic toxicity, or exhibit the fundamental flaw of exponentially overpowering the contributions of the individual drugs in the dose-response. This specifically leads to issues when drug combinations exhibit antagonistic toxicity, in which case the toxicity probability gets vanishingly small as doses get very large. We put forward additional constraints inspired by Paracelsus' intuition of "the dose makes the poison" which avoid this flaw and present an improved interaction model which is compatible with these constraints. We create instructive data scenarios that showcase the improved behavior of this more constrained drug-drug interaction model in terms of preventing further dosing at overly toxic dose combinations and more sensible dose-finding under antagonistic drug toxicity. This model is now available in the open-source OncoBayes2 R package that implements the BLRM framework for an arbitrary number of drugs and trial arms.

A Robust Proposal for Heteroscedastic Dose–Response Models with an Application to Interaction Analysis

Monotonic Nonparametric Dose Response Model

Marginalization in nonlinear mixed-effects models with an application to dose-response analysis

Dose-Response Curve Estimation: A Semiparametric Mixture Approach

A Bayesian Quasi-Likelihood Design for Identifying the Minimum Effective Dose and Maximum Utility Dose in Dose-Ranging Studies

Bayesian Nonparametric Risk Assessment in Developmental Toxicity Studies with Ordinal Responses

Response-adaptive dose-finding under model uncertainty

Inferring Synergistic and Antagonistic Interactions in Mixtures of Exposures

Convex Mixture Regression for Quantitative Risk Assessment

Adaptive designs for identifying optimal biological dose for molecularly targeted agents.

Semi-parametric Benchmark Dose Analysis with Monotone Additive Models

Dose Selection Balancing Efficacy and Toxicity Using Bayesian Model Averaging

Quantitative Risk Assessment: Developing a Bayesian Approach to Dichotomous Dose-Response Uncertainty

Principled Drug-Drug Interaction Terms for Bayesian Logistic Regression Models of Drug Safety in Oncology Phase I Combination Trials

A Comparison of Statistical Methods for Studying Interactions of Chemical Mixtures

Benchmark Dose Analysis via Nonparametric Regression Modeling

Robust Emax Model Fitting: Addressing Nonignorable Missing Binary Outcome in Dose-Response Analysis

Estimating Long-term Heterogeneous Dose-response Curve: Generalization Bound Leveraging Optimal Transport Weights

D-optimal Approximate Design for Binary Regression and Quantal Response in Toxicology Studies

Optimal designs for dose–response models with linear effects of covariates

Choosing statistical models to assess biological interaction as a departure from additivity of effects